Evidence map›Paper›PMID 39431558›Full record

ArticleRenal failure2024

Development and validation of a chronic kidney disease progression model using patient-level simulations.

Mafalda Ramos, Laetitia Gerlier, Anastasia Uster, Louise Muttram, Dominik Steubl, Andrew H Frankel, Mark Lamotte

Abstract readValidation Study
In one paragraph

Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mafalda RamosIQVIA Global HEOR, Oeiras, Portugal.
Laetitia GerlierIQVIA Global HEOR, Zaventem, Belgium.
Anastasia UsterBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Louise MuttramBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Dominik SteublBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Andrew H FrankelImperial College Healthcare NHS Trust, London, UK.
Mark LamotteIQVIA Global HEOR, Zaventem, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic disease progression models are available for several highly prevalent conditions. For chronic kidney disease (CKD), the scope of existing progression models is limited to the risk of kidney failure and major cardiovascular (CV) events. The aim of this project was to develop a comprehensive CKD progression model (CKD-PM) that simulates the risk of CKD progression and a broad range of complications in patients with CKD. A series of literature reviews informed the selection of risk factors and identified existing risk equations/algorithms for kidney replacement therapy (KRT), CV events, other CKD-related complications, and mortality. Risk equations and transition probabilities were primarily sourced from publications produced by large US and international CKD registries. A patient-level, state-transition model was developed with health states defined by the Kidney Disease Improving Global Outcomes categories. Model validation was performed by comparing predicted outcomes with observed outcomes in the source cohorts used in model development (internal validation) and other cohorts (external validation). The CKD-PM demonstrated satisfactory modeling properties. Accurate prediction of all-cause and CV mortality was achieved without calibration, while prediction of CV events through CKD-specific equations required implementation of a calibration factor to balance time-dependent versus baseline risk. Predicted annual changes in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio were acceptable in comparison to external values. A flexible eGFR threshold for KRT equations enabled accurate prediction of these events. This CKD-PM demonstrated reliable modeling properties. Both internal and external validation revealed robust outcomes.

Indexed as

Disease ProgressionGlomerular Filtration RateRenal Insufficiency, ChronicAgedCardiovascular DiseasesFemaleHumansMaleMiddle AgedRenal Replacement TherapyRisk AssessmentRisk FactorsChronic kidney diseasedisease progression modelmicrosimulationvalidation

Identifiers

PMID39431558
PMCPMC11494709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.